Savitex, a drug spray derived from natural marijuana instead of synthetic sources and developed by British pharmaceutical company GW Pharma, may be available in America soon.
According to the Huffington Post, GW Pharma is already into clinical trials to test the drug's ability to relieve cancer pain. The FDA estimates the end of 2013 as the most likely approval date.
Savitex is already being used in Canada, New Zealand, and other European countries as a treatment for muscle spasms associated with multiple sclerosis. It is estimated that 10-30% of European patients currently smoke marijuana to ease the pain and symptoms of multiple sclerosis.
Savitex's most effective ingredients are delta 9-THC and cannabidiol, but even though the spray is a cannibis extract, the chemicals that cause marijuana users to get intoxicated are not in the drug.
GW Pharma actually grows its own marijuana for the manufacture of the drug, using growing technology used by illegal growers. They process the cannabis to make an oil by making a tincture and heating it under pressure. They then add flavor oils to mask the taste of the cannabis and some preservatives.
In July 2011, the Department of Justice’s Drug Enforcement Administration killed a petition to reclassify marijuana as a drug with important medicinal properties, citing that it has “no accepted medical use," as ABC News reports.